AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17615455 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient pulmonary rehabilitation program (4 sessions with inpatients and 4 weeks at home)
Number of subjects: 42
Study 17615455 — intervention group
Group type: COMPARATOR
Intervention: Home based pulmonary rehabilitation program (control group)
Number of subjects: 42
Study 15230337 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole formulation 1
Number of subjects: 20
Study 15230337 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole formulation 2
Number of subjects: 20
Study 12227646 — intervention group
Group type: EXPERIMENTAL
Intervention: DCLHb (10% solution, approximately 1000 mg/kg)
Number of subjects: 24
Study 9785750 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 100
Study 9785750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7631339 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment
Number of subjects: 34
Study 7631339 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (air)
Number of subjects: 34
Study 2649149 — intervention group
Group type: EXPERIMENTAL
Intervention: soluble slow-release artificial tear insert
Number of subjects: 22
Study 378317 — intervention group
Group type: EXPERIMENTAL
Intervention: Mysteclin syrup (tetracycline hydrochloride and amphotericin) used as a mouthwash
Number of subjects: 20
Study 378317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31255801 — intervention group
Group type: EXPERIMENTAL
Intervention: mySmartSkin intervention
Number of subjects: 441
Study 31255801 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 441
Study 28318448 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary incontinence (53 patients)
Number of subjects: 144
Study 28318448 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological resilience (PR)
Number of subjects: 144
Study 28318448 — intervention group
Group type: COMPARATOR
Intervention: No urinary incontinence (91 patients)
Number of subjects: 144
Study 25877360 — intervention group
Group type: EXPERIMENTAL
Intervention: LF rTMS and VR training
Number of subjects: 112
Study 25877360 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS and VR training
Number of subjects: 112
Study 23148243 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol (7%, 14%, and 21% dietary DM)
Number of subjects: 72
Study 21864626 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mg intradermally (id) HIV‐DNA vaccine
Number of subjects: 60
Study 21864626 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.8mg intramuscularly (im) HIV‐DNA vaccine
Number of subjects: 60
Study 21864626 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant MVA (10^8 pfu)
Number of subjects: 60
Study 21864626 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐DNA vaccine
Number of subjects: 60
Study 21864626 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMC assay
Number of subjects: 60
Study 21864626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19707015 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (statin group)
Number of subjects: 40
Study 19707015 — intervention group
Group type: COMPARATOR
Intervention: Diet (diet group)
Number of subjects: 40
Study 17763935 — intervention group
Group type: EXPERIMENTAL
Intervention: therapy to normalize homocysteine plasma level
Number of subjects: 48
Study 17763935 — intervention group
Group type: COMPARATOR
Intervention: no therapy to normalize homocysteine plasma level
Number of subjects: 48
Study 16445556 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (8-24 mg/day)
Number of subjects: 18
Study 16445556 — intervention group
Group type: COMPARATOR
Intervention: Methadone (40-100 mg/day)
Number of subjects: 18
Study 16445556 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 18
Study 16445556 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 18
Study 16445556 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study 12563623 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbifer Durules (1 tablet/d) for 4 weeks
Number of subjects: 24
Study 10522149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract with arginine and magnesium
Number of subjects: 20
Study 10522149 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemorheology
Number of subjects: 20
Study 8901659 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate oral anticoagulation (INR 2.0 to 3.0)
Number of subjects: 380
Study 8901659 — intervention group
Group type: COMPARATOR
Intervention: Standard oral anticoagulation (INR 3.0 to 4.5)
Number of subjects: 380
Study 1930006 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate 320
Number of subjects: 300
Study 1930006 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol 300
Number of subjects: 300
Study 6176321 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy plus six courses of MOPP chemotherapy
Number of subjects: 0
Study 6176321 — intervention group
Group type: EXPERIMENTAL
Intervention: Three or four courses of MOPP before radiotherapy
Number of subjects: 0
Study 6176321 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (MOPP-bleomycin)
Number of subjects: 0
Study 6176321 — intervention group
Group type: EXPERIMENTAL
Intervention: MOP-BAP (MOPP-bleomycin plus doxorubicin)
Number of subjects: 0
Study 31812755 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous reperfusion (SR) prior to primary percutaneous coronary intervention (pPCI)
Number of subjects: 683
Study 31812755 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous reperfusion (SR)
Number of subjects: 683
Study 31394603 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2)
Number of subjects: 143
Study 31394603 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 143
Study 31394603 — intervention group
Group type: COMPARATOR
Intervention: COBRIT composite scoring
Number of subjects: 143
Study 28118369 — intervention group
Group type: EXPERIMENTAL
Intervention: Duchenne Muscular Dystrophy (DMD) group
Number of subjects: 45
Study 28118369 — intervention group
Group type: COMPARATOR
Intervention: Healthy Typical Development (TD) control group
Number of subjects: 45
Study 26314308 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-osmolarity oral rehydration solution (ORS) (osmolarity: 245, sodium: 75) with added potassium (20 mmol/l)
Number of subjects: 110
Study 26314308 — intervention group
Group type: COMPARATOR
Intervention: Modified ReSoMal (osmolarity: 300, sodium: 45)
Number of subjects: 110
Study 23364255 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin (20 mg 2-4 hours before PCI)
Number of subjects: 125
Study 23364255 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 125
Study 21371128 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin gel microsphere 0.04% or 0.1%
Number of subjects: 25
Study 20469685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) at a dose of 10 mg/kg body weight once at night for 3 months
Number of subjects: 450
Study 20469685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 450
Study 17869300 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal approach
Number of subjects: 40
Study 17869300 — intervention group
Group type: COMPARATOR
Intervention: Retroperitoneal approach
Number of subjects: 40
Study 15164114 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 IU vitamin A supplementation (VA group; n=970)
Number of subjects: 3636
Study 15164114 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg iron supplementation (Fe group; n=978)
Number of subjects: 3636
Study 15164114 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined supplementation of 10,000 IU vitamin A and 60 mg iron (VAFe group; n=1042)
Number of subjects: 3636
Study 15164114 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=626)
Number of subjects: 3636
Study 11529465 — intervention group
Group type: EXPERIMENTAL
Intervention: Up-front SCT with Dexa-BEAM chemotherapy followed by myeloablative regimens
Number of subjects: 55
Study 11529465 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage SCT with Dexa-BEAM chemotherapy followed by myeloablative regimens
Number of subjects: 55
Study 9476088 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 93
Study 9476088 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 93
Study 9476088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 7515507 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (80 mg/day for 5 days)
Number of subjects: 0
Study 7515507 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute dexamethasone administration
Number of subjects: 0
Study 7515507 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic corticosterone administration
Number of subjects: 0
Study 3652932 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring program for theophylline
Number of subjects: 169
Study 3652932 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of the therapeutic drug monitoring program
Number of subjects: 169
Study 3652932 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinstatement of the therapeutic drug monitoring program
Number of subjects: 169
Study 31904295 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) + Treatment as Usual (TAU)
Number of subjects: 94
Study 31904295 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 94
Study 31904295 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 94
Study 31046423 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice daily
Number of subjects: 11955
Study 31046423 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran (high-dose)
Number of subjects: 11955
Study 31046423 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran (low-dose)
Number of subjects: 11955
Study 27893033 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid for OA of the knee (40-minute video describing risks and benefits of TKR surgery)
Number of subjects: 336
Study 27893033 — intervention group
Group type: COMPARATOR
Intervention: Control group (no decision aid)
Number of subjects: 336
Study 27893033 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid for OA of the knee
Number of subjects: 336
Study 26152434 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabby (conversational agent system)
Number of subjects: 100
Study 26152434 — intervention group
Group type: COMPARATOR
Intervention: Control group (received a letter indicating health risks)
Number of subjects: 100
Study 23478546 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided internal jugular vein access
Number of subjects: 150
Study 23478546 — intervention group
Group type: COMPARATOR
Intervention: Landmark-guided subclavian/internal jugular vein access
Number of subjects: 150
Study 20534818 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (60 mg) administered with a standard high-fat meal
Number of subjects: 32
Study 20534818 — intervention group
Group type: COMPARATOR
Intervention: Edoxaban (60 mg) administered in a fasted state
Number of subjects: 32
Study 19671472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa powder (20 g/day) with 250 mL of skimmed milk
Number of subjects: 42
Study 19671472 — intervention group
Group type: COMPARATOR
Intervention: Skimmed milk (500 mL/day)
Number of subjects: 42
Study 17273659 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin, 20 mg/day (N = 20)
Number of subjects: 41
Study 17273659 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin, 1.7 g/day (N = 21)
Number of subjects: 41
Study 17273659 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 41
Study 14742393 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE)
Number of subjects: 60
Study 14742393 — intervention group
Group type: COMPARATOR
Intervention: Single-shot spinal (SSS)
Number of subjects: 60
Study 14742393 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE) (no-catheter)
Number of subjects: 60
Study 12392340 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Research Arm (ARA) test
Number of subjects: 63
Study 12392340 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-item scale from ARA test
Number of subjects: 63
Study 10215947 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative serum HCV PCR
Number of subjects: 132
Study 10215947 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV RNA titres
Number of subjects: 132
Study 10215947 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver histology assessed using modified histological activity index (HAI)
Number of subjects: 132
Study 10215947 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative HCV PCR in liver biopsies
Number of subjects: 132
Study 10215947 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum HCV quantification
Number of subjects: 132
Study 8555780 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated blood grouping by gel technology (ID-Sampler II)
Number of subjects: 0
Study 8555780 — intervention group
Group type: COMPARATOR
Intervention: Routine microtitre plate and gel techniques
Number of subjects: 0
Study 2925055 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Is‐5‐Mn
Number of subjects: 23
Study 2925055 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg Is‐5‐Mn
Number of subjects: 23
Study 2925055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 655957 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 82
Study 655957 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for radiation failures
Number of subjects: 82
Study 655957 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiation
Number of subjects: 82
Study 29696401 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest adherence to the Mediterranean diet (3rd tertile) and highest total leisure-time physical activity (3rd tertile)
Number of subjects: 7356
Study 29696401 — intervention group
Group type: EXPERIMENTAL
Intervention: Total, light, and moderate-to-vigorous leisure-time physical activity
Number of subjects: 7356
Study 27643690 — intervention group
Group type: EXPERIMENTAL
Intervention: Licorice flavonoid oil (LFO) 300 mg/day for 16 weeks
Number of subjects: 50
Study 27643690 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one capsule/day for 16 weeks)
Number of subjects: 50
Study 25824795 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (conducted by public health midwives)
Number of subjects: 520
Study 25824795 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 520
Study 22893557 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mL/kg calfactant by LMA (experimental)
Number of subjects: 26
Study 22893557 — intervention group
Group type: COMPARATOR
Intervention: Continued on nCPAP (control)
Number of subjects: 26
Study 20687194 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative therapy (NT) plus escitalopram
Number of subjects: 72
Study 20687194 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram plus usual care
Number of subjects: 72
Study 19136489 — intervention group
Group type: EXPERIMENTAL
Intervention: RV apex (RVA)
Number of subjects: 73
Study 19136489 — intervention group
Group type: COMPARATOR
Intervention: RV high septum (RVHS)
Number of subjects: 73
Study 17923538 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of fellow eyes at risk for choroidal neovascularization (CNV)
Number of subjects: 364
Study 17923538 — intervention group
Group type: EXPERIMENTAL
Intervention: Characteristics of incident lesions
Number of subjects: 364
Study 17923538 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity at the time of incidence
Number of subjects: 364
Study 15516378 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused ultrasound therapy
Number of subjects: 76
Study 11202490 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated-exposure condition (five repetitions of 5 stimuli)
Number of subjects: 0
Study 11202490 — intervention group
Group type: COMPARATOR
Intervention: Single-exposure condition (5-ms exposures of 25 stimuli each shown once)
Number of subjects: 0
Study 11202490 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated-exposure condition
Number of subjects: 0
Study 11202490 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously exposed stimuli
Number of subjects: 0
Study 11202490 — intervention group
Group type: EXPERIMENTAL
Intervention: New but similar stimuli
Number of subjects: 0
Study 11202490 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimuli from a different category
Number of subjects: 0
Study 9364418 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg codeine
Number of subjects: 82
Study 9364418 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 82
Study 9364418 — intervention group
Group type: EXPERIMENTAL
Intervention: Both codeine and placebo
Number of subjects: 82
Study 1556249 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 49
Study 1556249 — intervention group
Group type: EXPERIMENTAL
Intervention: Meridol I
Number of subjects: 49
Study 1556249 — intervention group
Group type: EXPERIMENTAL
Intervention: Meridol II
Number of subjects: 49
Study 1556249 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine
Number of subjects: 49
Study 1556249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 1556249 — intervention group
Group type: EXPERIMENTAL
Intervention: Meridol
Number of subjects: 49
Study 4011068 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally inserted rayon and cotton tampons (regular, super, super-plus)
Number of subjects: 100
Study 4011068 — intervention group
Group type: EXPERIMENTAL
Intervention: Rayon polyacrylate tampon
Number of subjects: 100
Study 4011068 — intervention group
Group type: COMPARATOR
Intervention: External sanitary protection
Number of subjects: 100
Study 31969269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine (modal dose <1.5, 1.5, 3 mg/d)
Number of subjects: 1775
Study 31969269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1775
Study 31969269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine (modal dose)
Number of subjects: 1775
Study 31969269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine (fixed dose 1.5 mg/d)
Number of subjects: 1775
Study 31174162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative adversity score
Number of subjects: 712
Study 31174162 — intervention group
Group type: EXPERIMENTAL
Intervention: Adversity quintile
Number of subjects: 712
Study 31174162 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic adversity
Number of subjects: 712
Study 31174162 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-child relationship adversity
Number of subjects: 712
Study 31174162 — intervention group
Group type: EXPERIMENTAL
Intervention: Child adversity
Number of subjects: 712
Study 31174162 — intervention group
Group type: COMPARATOR
Intervention: Saliva cortisol measures
Number of subjects: 712
Study 28440810 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0
Study 28440810 — intervention group
Group type: COMPARATOR
Intervention: Amphetamine
Number of subjects: 0
Study 25693969 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture at four acupoints on the Stomach Meridian
Number of subjects: 20
Study 25693969 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture at four acupoints on the Gallbladder Meridian
Number of subjects: 20
Study 23527977 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NV)
Number of subjects: 63
Study 23527977 — intervention group
Group type: COMPARATOR
Intervention: Invasive ventilation (IV)
Number of subjects: 63
Study 21310831 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal oleic acid (18:1 load: 0.78 kcal/min)
Number of subjects: 19
Study 21310831 — intervention group
Group type: COMPARATOR
Intervention: Recent dietary intake
Number of subjects: 19
Study 19738111 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanford V
Number of subjects: 520
Study 19738111 — intervention group
Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 520
Study 18626140 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine (12 mg)
Number of subjects: 18
Study 18626140 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine plus ephedrine (Chlorphedra: 12 mg C + 50 mg ephedrine)
Number of subjects: 18
Study 18626140 — intervention group
Group type: COMPARATOR
Intervention: Chlorpheniramine plus ephedrine (Chlorphedra)
Number of subjects: 18
Study 14747117 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone prophylaxis in group 1B (n=100)
Number of subjects: 300
Study 14747117 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis in group 1A (n=100)
Number of subjects: 300
Study 11426104 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hypercapnia
Number of subjects: 57
Study 11426104 — intervention group
Group type: COMPARATOR
Intervention: Intermittent boluses of saline injected intrathecally (Control)
Number of subjects: 57
Study 9261702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (for TBSA < 35%)
Number of subjects: 23
Study 9261702 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for TBSA < 35%)
Number of subjects: 23
Study 9261702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (for TBSA ≥ 35%)
Number of subjects: 23
Study 9261702 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted antibiotics (for TBSA ≥ 35%)
Number of subjects: 23
Study 8418349 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine withdrawal
Number of subjects: 30
Study 3536400 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g sucralfate suspension four times daily
Number of subjects: 134
Study 3536400 — intervention group
Group type: COMPARATOR
Intervention: 150 mg ranitidine tablet twice daily
Number of subjects: 134
Study 3536400 — intervention group
Group type: COMPARATOR
Intervention: ranitidine
Number of subjects: 134